Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer

Abstract We explored the prognostic impact of simple indices that reflect immunological milieu (neutrophils to lymphocyte ratio [NLR] and systemic immune-inflammation [SII]) in 49 platinum-resistant relapsed ovarian cancer patients. The median progression-free survival (PFS) overall (OS) were 4 8 months, respectively. Patients with a lower NLR (?2.89) had better PFS (5 vs. 2 months [p = 0.02]) OS (9 5 0.20]). Factors associated worse > 2.8 (hazard [HR] =2.32, p 0.02) SII 639 (HR =3.70, 0.002). independently predicted =4.13, 0.03). Future studies should study validity inflammatory markers could consider incorporating it as biomarker clinical trials.